A Study of MET233 in Combination With MET097
Phase 1/2
132
about 11 months
18–75
1 site in CA
What this study is about
Researchers are testing a treatment combination (MET233 and MET097) for people with obesity or overweight, possibly including those with diabetes. The trial will examine the safety and how well the medication works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MET233
- 2.Take MET233 and MET097
- 3.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part A: Occurrence of treatment-emergent adverse events (TEAEs), Part B: Occurrence of treatment-emergent adverse events (TEAEs), Part C: Occurrence of treatment-emergent adverse events (TEAEs)
Secondary: Part A: Area under the concentration versus time curve (AUC), Part A: Maximum observed concentration (Cmax), Part A: Percent change from baseline in body weight, Part A: Time to maximum observed concentration (Tmax), Part B: Area under the concentration versus time curve (AUC), Part B: Maximum observed concentration (Cmax), Part B: Percent change from baseline in body weight, Part B: Time to maximum observed concentration (Tmax)
Endocrinology